Skip to main content
Premium Trial:

Request an Annual Quote

OncoMed, Fluidigm to Analyze Tumor Cell Populations

NEW YORK (GenomeWeb News) – OncoMed Pharmaceuticals and Fluidigm have entered into a collaboration to use microfluidic tools to analyze the heterogeneity of tumor cells, including cancer stem cells, the companies said yesterday.

The partnership will combine Fluidigm's microfluidic platforms with OncoMed's cancer stem cell sorting technology to generate tools to analyze, quantify and develop treatments directed at a highly tumorigenic cell population, the companies said.

Initially, OncoMed, based in Redwood City, Calif., will use Fluidigm's BioMark system and Dynamic Array integrated fluidic circuits to analyze gene expression of solid tumors at the whole tumor and single-cell level. This phase will track changes in cancer stem cells from human tumors following treatment with OncoMed's therapeutic monoclonal antibodies.

The companies will then apply these technologies to analyze tumor heterogeneity and cancer stem cell frequency across OncoMed's human tumor bank, which includes approximately 100 human tumor biopsies that have been engrafted and minimally passaged in immunocompromised mice.

The collaboration may eventually include novel and next-generation microfluidic and tissue sample-preparation technologies currently being developed by South San Francisco, Calif.-based Fluidigm, the companies said.

Financial terms of the agreement were not disclosed.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.